Enzo Biochem Announces Settlement Agreement with PerkinElmer

  Enzo Biochem Announces Settlement Agreement with PerkinElmer

Business Wire

NEW YORK -- June 23, 2014

Enzo Biochem, Inc. (NYSE:ENZ) (the "Company"), along with its subsidiary Enzo
Life Sciences, Inc. entered into a Settlement with PerkinElmer, Inc. and
PerkinElmer Health Sciences, Inc. (NYSE:PKI) with respect to an action between
the Company and PerkinElmer before the U.S. District Court, Southern District
of New York, Case No 03-CV-3817. PerkinElmer, Inc. has agreed to pay
$7,000,000 in escrow in settlement pursuant to the Agreement.

About Enzo Biochem

Enzo Biochem is a pioneer in molecular diagnostics, leading the convergence of
clinical laboratories, life sciences and therapeutics through the development
of unique diagnostic platform technologies that provide numerous advantages
over previous standards. A global company, Enzo Biochem utilizes
cross-functional teams to develop and deploy products systems and services
that meet the ever-changing and rapidly growing needs of health care both
today and into the future. Underpinning Enzo Biochem's products and
technologies is a broad and deep intellectual property portfolio, with patent
coverage across a number of key enabling technologies.

Except for historical information, the matters discussed in this news release
may be considered forward-looking" statements within the meaning of Section
27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended Such statements include
declarations regarding the intent, belief or current expectations of the
Company and its management, including those related to cash flow, gross
margins, revenues, and expenses are dependent on a number of factors outside
of the control of the company including, inter alia, the markets for the
Company's products and services, costs of goods and services, other expenses,
government regulations, litigations, and general business conditions. See Risk
Factors in the Company's Form 10-K for the fiscal year ended July 31, 2013.
Investors are cautioned that any such forward-looking statements are not
guarantees of future performance and involve a number of risks and
uncertainties that could materially affect actual results. The Company
disclaims any obligations to update any forward-looking statement as a result
of developments occurring after the date of this press release.

Contact:

For Enzo Biochem, Inc.
Anreder & Company
Steven Anreder, 212-532-3232
steven.anreder@anreder.com
or
CEOcast, Inc.
Michael Wachs, 212-732-4300
mwachs@ceocast.com
 
Press spacebar to pause and continue. Press esc to stop.